Key Highlights

  • Karyopharm Therapeutics (NASDAQ:KPTI) entered Chapter 11 on November 2, 2026, and its filing states that existing common stock would collect no distribution under the prepackaged plan.
  • Pacific Biosciences (NASDAQ:PACB) will publish third quarter results on November 4, 2026, following second quarter Revenue of USD 39.0 million and a GAAP net loss of USD 44.7 million.
  • Ardelyx (NASDAQ:ARDX) posted third quarter revenue of USD 127.7 million on November 3, 2026, up from USD 110.3 million, and recorded a net loss of USD 0.7 million.
  • Ocugen (NASDAQ:OCGN) had USD 100.4 million of cash at June 30, 2026, after issuing USD 115 million of 6.75% convertible notes.

Karyopharm Therapeutics (NASDAQ:KPTI): Chapter 11 Where Equity Is Expected to Be Wiped Out

A commercial-stage drug company headquartered in Newton, Massachusetts, Karyopharm Therapeutics (NASDAQ:KPTI) told investors in a Form 8-K dated November 2, 2026 that it had struck a restructuring support agreement and filed Chapter 11 petitions in the Southern District of Texas. Under the proposed arrangement, private firm Ayrmid Ltd. would combine with a restructured Karyopharm, a transaction projected to finish in early 2027, and the filing makes clear that common and convertible preferred holders would get nothing. The company is asking the court for a USD 110 million superpriority debtor-in-possession facility, with up to USD 55 million in fresh money and the remainder converting existing loans. At the close of the first quarter, cash stood at USD 90.9 million against term Loan principal of USD 124.6 million, the stockholders' Deficit reached USD 265.6 million, and management flagged substantial doubt about its ability to keep operating as a going concern. Published market data showed USD 0.10, a 9.17% rise, on roughly 24.457 million shares, although the snapshot is undated. The filing calls trading during the cases highly speculative, and in a Penny Stock a few orders can swing the quote. Whether Nasdaq Listing Rules will still apply has not been confirmed, and a rival bid would be the main development to monitor.

Pacific Biosciences (NASDAQ:PACB): A Preview of Falling Cash and a Trimmed Outlook

Long-read DNA sequencing instruments and consumables are the product line of Pacific Biosciences (NASDAQ:PACB), whose third quarter results and call are slated for November 4, 2026. This is a preview, because none of those figures had been checked when this was drafted. Second quarter revenue came in at USD 39.0 million, slightly below the USD 39.8 million of the prior year, and the GAAP net loss was USD 44.7 million, or USD 0.14 per share. Cash, equivalents and investments measured USD 236.9 million at June 30, 2026, down from USD 314.7 million a year before, a decline of roughly USD 77.8 million by simple subtraction. The full-year revenue forecast of USD 155 million to USD 165 million sits below the USD 165 million to USD 175 million outlook issued alongside first quarter results. GAAP gross Margin registered 32%, and the first quarter filing listed net convertible senior notes of USD 644.1 million. Published market data put the stock at USD 2.57, a 5.13% gain, on 7.452 million shares with no date. As a penny stock, a pre-release rally can be erased once actual figures appear, and the coming report will show whether margins and cash balances have leveled off.

Ardelyx (NASDAQ:ARDX): USD 127.7 Million of Revenue Beside a Small Net Loss

Ardelyx (NASDAQ:ARDX) published third quarter 2026 figures on November 3, 2026 showing total revenue of USD 127.7 million, of which USD 125.5 million was product sales that rose 19%. Its portfolio of medicines for gastrointestinal and kidney conditions is led by IBSRELA, which generated USD 96.3 million (up 23%), followed by XPHOZAH at USD 29.2 million (up 7%). Operating Income came to USD 4.0 million, compared with USD 4.7 million a year earlier, and after USD 15.1 million of share-based pay the Bottom Line showed a USD 0.7 million net loss. Cash plus short-term investments reached USD 285.3 million. Full-year guidance was reaffirmed at USD 350 million to USD 370 million for IBSRELA and USD 110 million to USD 120 million for XPHOZAH. Its Phase 3 ACCEL study finished enrollment ahead of schedule, with topline results expected in the second half of 2027, and a fresh Patent is due to be granted on November 10, 2026. Published market data recorded USD 3.14, a 3.47% gain, on around 2.8 million shares without a snapshot date. A move that small signals little, since gains of this size often reverse.

Ocugen (NASDAQ:OCGN): USD 100.4 Million of Cash Built on Convertible Debt

Gene therapies aimed at blinding eye diseases are the focus of Ocugen (NASDAQ:OCGN). Cash, equivalents and restricted cash were USD 100.4 million at June 30, 2026, up from USD 18.9 million at the end of 2025, after the May 5 pricing of USD 115 million in 6.75% convertible senior notes maturing in 2034. The starting conversion price is roughly USD 2.68, and the first coupon falls due November 15, 2026. Losses over the first six months totaled USD 44.1 million, so the cash lasts about 4.5 quarters at the second quarter burn rate, a loose estimate that leaves out non-cash charges. OCU400 has completed Phase 3 enrollment, with topline data slated for the first quarter of 2027 and a BLA targeted for the second quarter of 2027. Shares outstanding climbed from 312.4 million to 339.0 million over six months, so dilution continues. Published market data showed USD 0.80, up 7.57%, on 2.766 million shares, with no date. The filings reviewed contain no Nasdaq minimum bid notice, and any penny stock gain can be given back. A binding term sheet with Roots Pharmaceutical covers potential payments of up to USD 255 million plus 22% royalties.

Where Things Stand

Karyopharm Therapeutics (NASDAQ:KPTI) changes hands near USD 0.10 even though its own filing expects common shareholders to receive nothing under the prepackaged plan, so the 9.17% quoted gain does not alter that picture. Pacific Biosciences (NASDAQ:PACB) heads into a November 4, 2026 release with revenue flat, a USD 44.7 million quarterly loss and shrinking cash. Ardelyx (NASDAQ:ARDX) pairs 19% product sales growth with a slim bottom line. Ocugen (NASDAQ:OCGN) holds enough money for several quarters but has no product sales yet. Each of these is a penny stock, so a handful of trades can move the quote, spreads may be wide and recent gains can unwind. Key dated events ahead are the November 4 and November 10 milestones, the court calendar in the Chapter 11 case and Ocugen's November 15 interest payment.